#Munich #UK #Caristo Diagnostics #Cardiovascular Disease #FAI-Score

Caristo Diagnostics Presents Groundbreaking Data at ESC Congress 2026

Caristo Diagnostics, a prominent name in artificial intelligence solutions for cardiovascular health, recently revealed significant findings at the European Society of Cardiology (ESC) Congress 2026. Under the leadership of the University of Oxford, the research showcased the potential of the FAI-Score™ biomarker to assess coronary inflammation via non-contrast cardiac CT scans, especially highlighting its ability to identify high-risk patients even when traditional coronary calcium assessments show zero.

The Importance of the FAI-Score™

The FAI-Score™ biomarker allows physicians to evaluate coronary inflammation effectively, which can be critical in understanding a patient’s cardiovascular risk. Traditionally, many standard tools overlook patients without apparent warning signals, creating a gap that can lead to fatal outcomes. The findings at the congress illuminated how this innovative scoring system can provide supplementary data, empowering healthcare providers to make informed decisions based on hidden risks.

Insights from the ORFAN-MAESTRIA Study

In addition to the FAI-Score™ data, Caristo introduced late-breaking research from the ORFAN-MAESTRIA study, examining how its AI technology could enhance predictions of stroke risk based on routine cardiac CT scans. This pivotal research consolidates Caristo's ongoing mission to redefine cardiovascular evaluations and drive better health outcomes.

Tackling Cardiovascular Mortality

Statistics show that cardiovascular disease continues to be the leading cause of mortality globally, with heart attacks accounting for a significant portion of these tragedies. Worryingly, a substantial number of first-time heart attacks are recorded among individuals deemed 'low-risk' through traditional assessments. As Steve Deitsch, CEO of Caristo Diagnostics, articulated, "Nearly 50% of first-time heart attacks occur in people classified as 'low-risk' by traditional cardiovascular risk assessments." This realization underscores the pressing need for progressive tools like the FAI-Score™.

The Broader Implications of FAI-Score™

Research presented at the conference emphasized that even in patients without standard modifiable risk factors, an elevated FAI-Score™ could correlate with a significantly higher risk of cardiovascular mortality. These insights not only validate Caristo's technological advancements but also stress the importance of looking beyond traditional metrics to capture a comprehensive view of patient health.

Future Directions in Cardiovascular Evaluation

As the conversation progressed in Munich, additional late-breaking data highlighted the potential of the FAI-Score™ to predict stroke risks independent of atrial fibrillation—a significant breakthrough demonstrated through a decade-long study involving over 81,000 patients.

Professor Charalambos Antoniades from the University of Oxford touted the promise of the platform, stating, "Looking ahead, the same scientific approach could be applied to other disease pathways, including left atrial myopathy, to help predict future cardioembolic stroke.” This forward-looking perspective offers hope for transitioning from reactive to proactive healthcare measures.

Conclusion

Caristo Diagnostics' groundbreaking data at the ESC Congress 2026 is not solely about numbers but the lives that can be saved through innovative technology. By harnessing AI-enabled tools like the FAI-Score™, healthcare providers can better assess risk and intervene earlier, ultimately changing the narrative around cardiovascular disease.

The journey is just beginning, and as Caristo continues to invest in research and development, the potential for life-saving interventions in the realm of cardiovascular health is beyond promising. This conference provided a crucial platform for advancing these discussions, combining scientific inquiry with practical implications for patient care.